Open16.550 | Close- |
Vol / Avg.155.414K / 686.019K | Mkt Cap1.007B |
Day Range16.510 - 17.010 | 52 Wk Range14.470 - 36.640 |
Pliant Therapeutics Stock (NASDAQ: PLRX) stock price, news, charts, stock research, profile.
Open16.550 | Close- |
Vol / Avg.155.414K / 686.019K | Mkt Cap1.007B |
Day Range16.510 - 17.010 | 52 Wk Range14.470 - 36.640 |
Q3 2023 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | (EXPECTED) | ||||||
REV |
Q2 2023 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | -0.710 | -0.700 | 0.0100 | ||||
REV | 880.000K | 248.000K | -632.000K |
Date | Analyst Firm | Analyst Name | Action | Rating | Action Price | Prior Price | Target |
---|---|---|---|---|---|---|---|
2023-09-27 | HC Wainwright & Co. | Ed Arce | Maintains | BuyBuy | Raises | 50.00 | 52.00 |
2023-09-27 | Needham | Joseph Stringer | Reiterates | BuyBuy | Maintains | - | 45.00 |
2023-09-15 | Needham | Joseph Stringer | Reiterates | BuyBuy | Maintains | - | 45.00 |
2023-08-29 | HC Wainwright & Co. | Ed Arce | Reiterates | BuyBuy | Maintains | - | 50.00 |
Ticker | Company | Chg % | Mkt Cap |
---|---|---|---|
PLRX | Pliant Therapeutics | 2.62% | 1B |
GHRS | GH Research | -1.62% | 538.4M |
SUPN | Supernus Pharmaceuticals | -1.39% | 1.5B |
VRNA | Verona Pharma | -0.18% | 1.3B |
WVE | WAVE Life Sciences | -3.83% | 546.4M |
You can purchase shares of Pliant Therapeutics (NASDAQ: PLRX) through any online brokerage.
Other companies in Pliant Therapeutics’s space includes: GH Research (NASDAQ:GHRS), Supernus Pharmaceuticals (NASDAQ:SUPN), Verona Pharma (NASDAQ:VRNA), WAVE Life Sciences (NASDAQ:WVE) and CymaBay Therapeutics (NASDAQ:CBAY).
The latest price target for Pliant Therapeutics (NASDAQ: PLRX) was reported by HC Wainwright & Co. on Wednesday, September 27, 2023. The analyst firm set a price target for 52.00 expecting PLRX to rise to within 12 months (a possible 208.97% upside). 35 analyst firms have reported ratings in the last year.
The stock price for Pliant Therapeutics (NASDAQ: PLRX) is $16.83 last updated Today at September 29, 2023 at 3:30 PM UTC.
There is no dividend information for Pliant Therapeutics.
Pliant Therapeutics’s Q3 earnings are confirmed for Tuesday, November 7, 2023.
There is no upcoming split for Pliant Therapeutics.
Pliant Therapeutics is in the Health Care sector and Pharmaceuticals industry. They are listed on the NASDAQ.
Pliant Therapeutics Stock (NASDAQ: PLRX) stock price, news, charts, stock research, profile.
Open16.550 | Close- |
Vol / Avg.155.414K / 686.019K | Mkt Cap1.007B |
Day Range16.510 - 17.010 | 52 Wk Range14.470 - 36.640 |
Q3 2023 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | (EXPECTED) | ||||||
REV |
Q2 2023 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | -0.710 | -0.700 | 0.0100 | ||||
REV | 880.000K | 248.000K | -632.000K |
Date | Analyst Firm | Analyst Name | Action | Rating | Action Price | Prior Price | Target |
---|---|---|---|---|---|---|---|
2023-09-27 | HC Wainwright & Co. | Ed Arce | Maintains | BuyBuy | Raises | 50.00 | 52.00 |
2023-09-27 | Needham | Joseph Stringer | Reiterates | BuyBuy | Maintains | - | 45.00 |
2023-09-15 | Needham | Joseph Stringer | Reiterates | BuyBuy | Maintains | - | 45.00 |
2023-08-29 | HC Wainwright & Co. | Ed Arce | Reiterates | BuyBuy | Maintains | - | 50.00 |
Ticker | Company | Chg % | Mkt Cap |
---|---|---|---|
PLRX | Pliant Therapeutics | 2.62% | 1B |
GHRS | GH Research | -1.62% | 538.4M |
SUPN | Supernus Pharmaceuticals | -1.39% | 1.5B |
VRNA | Verona Pharma | -0.18% | 1.3B |
WVE | WAVE Life Sciences | -3.83% | 546.4M |
You can purchase shares of Pliant Therapeutics (NASDAQ: PLRX) through any online brokerage.
Other companies in Pliant Therapeutics’s space includes: GH Research (NASDAQ:GHRS), Supernus Pharmaceuticals (NASDAQ:SUPN), Verona Pharma (NASDAQ:VRNA), WAVE Life Sciences (NASDAQ:WVE) and CymaBay Therapeutics (NASDAQ:CBAY).
The latest price target for Pliant Therapeutics (NASDAQ: PLRX) was reported by HC Wainwright & Co. on Wednesday, September 27, 2023. The analyst firm set a price target for 52.00 expecting PLRX to rise to within 12 months (a possible 208.97% upside). 35 analyst firms have reported ratings in the last year.
The stock price for Pliant Therapeutics (NASDAQ: PLRX) is $16.83 last updated Today at September 29, 2023 at 3:30 PM UTC.
There is no dividend information for Pliant Therapeutics.
Pliant Therapeutics’s Q3 earnings are confirmed for Tuesday, November 7, 2023.
There is no upcoming split for Pliant Therapeutics.
Pliant Therapeutics is in the Health Care sector and Pharmaceuticals industry. They are listed on the NASDAQ.
Pliant Therapeutics Stock (NASDAQ: PLRX) stock price, news, charts, stock research, profile.
Open16.550 | Close- |
Vol / Avg.155.414K / 686.019K | Mkt Cap1.007B |
Day Range16.510 - 17.010 | 52 Wk Range14.470 - 36.640 |
Q3 2023 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | (EXPECTED) | ||||||
REV |
Q2 2023 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | -0.710 | -0.700 | 0.0100 | ||||
REV | 880.000K | 248.000K | -632.000K |
Date | Analyst Firm | Analyst Name | Action | Rating | Action Price | Prior Price | Target |
---|---|---|---|---|---|---|---|
2023-09-27 | HC Wainwright & Co. | Ed Arce | Maintains | BuyBuy | Raises | 50.00 | 52.00 |
2023-09-27 | Needham | Joseph Stringer | Reiterates | BuyBuy | Maintains | - | 45.00 |
2023-09-15 | Needham | Joseph Stringer | Reiterates | BuyBuy | Maintains | - | 45.00 |
2023-08-29 | HC Wainwright & Co. | Ed Arce | Reiterates | BuyBuy | Maintains | - | 50.00 |
Ticker | Company | Chg % | Mkt Cap |
---|---|---|---|
PLRX | Pliant Therapeutics | 2.62% | 1B |
GHRS | GH Research | -1.62% | 538.4M |
SUPN | Supernus Pharmaceuticals | -1.39% | 1.5B |
VRNA | Verona Pharma | -0.18% | 1.3B |
WVE | WAVE Life Sciences | -3.83% | 546.4M |
You can purchase shares of Pliant Therapeutics (NASDAQ: PLRX) through any online brokerage.
Other companies in Pliant Therapeutics’s space includes: GH Research (NASDAQ:GHRS), Supernus Pharmaceuticals (NASDAQ:SUPN), Verona Pharma (NASDAQ:VRNA), WAVE Life Sciences (NASDAQ:WVE) and CymaBay Therapeutics (NASDAQ:CBAY).
The latest price target for Pliant Therapeutics (NASDAQ: PLRX) was reported by HC Wainwright & Co. on Wednesday, September 27, 2023. The analyst firm set a price target for 52.00 expecting PLRX to rise to within 12 months (a possible 208.97% upside). 35 analyst firms have reported ratings in the last year.
The stock price for Pliant Therapeutics (NASDAQ: PLRX) is $16.83 last updated Today at September 29, 2023 at 3:30 PM UTC.
There is no dividend information for Pliant Therapeutics.
Pliant Therapeutics’s Q3 earnings are confirmed for Tuesday, November 7, 2023.
There is no upcoming split for Pliant Therapeutics.
Pliant Therapeutics is in the Health Care sector and Pharmaceuticals industry. They are listed on the NASDAQ.
Pliant Therapeutics Stock (NASDAQ: PLRX) stock price, news, charts, stock research, profile.
Open16.550 | Close- |
Vol / Avg.155.414K / 686.019K | Mkt Cap1.007B |
Day Range16.510 - 17.010 | 52 Wk Range14.470 - 36.640 |
Q3 2023 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | (EXPECTED) | ||||||
REV |
Q2 2023 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | -0.710 | -0.700 | 0.0100 | ||||
REV | 880.000K | 248.000K | -632.000K |
Date | Analyst Firm | Analyst Name | Action | Rating | Action Price | Prior Price | Target |
---|---|---|---|---|---|---|---|
2023-09-27 | HC Wainwright & Co. | Ed Arce | Maintains | BuyBuy | Raises | 50.00 | 52.00 |
2023-09-27 | Needham | Joseph Stringer | Reiterates | BuyBuy | Maintains | - | 45.00 |
2023-09-15 | Needham | Joseph Stringer | Reiterates | BuyBuy | Maintains | - | 45.00 |
2023-08-29 | HC Wainwright & Co. | Ed Arce | Reiterates | BuyBuy | Maintains | - | 50.00 |
Ticker | Company | Chg % | Mkt Cap |
---|---|---|---|
PLRX | Pliant Therapeutics | 2.62% | 1B |
GHRS | GH Research | -1.62% | 538.4M |
SUPN | Supernus Pharmaceuticals | -1.39% | 1.5B |
VRNA | Verona Pharma | -0.18% | 1.3B |
WVE | WAVE Life Sciences | -3.83% | 546.4M |
You can purchase shares of Pliant Therapeutics (NASDAQ: PLRX) through any online brokerage.
Other companies in Pliant Therapeutics’s space includes: GH Research (NASDAQ:GHRS), Supernus Pharmaceuticals (NASDAQ:SUPN), Verona Pharma (NASDAQ:VRNA), WAVE Life Sciences (NASDAQ:WVE) and CymaBay Therapeutics (NASDAQ:CBAY).
The latest price target for Pliant Therapeutics (NASDAQ: PLRX) was reported by HC Wainwright & Co. on Wednesday, September 27, 2023. The analyst firm set a price target for 52.00 expecting PLRX to rise to within 12 months (a possible 208.97% upside). 35 analyst firms have reported ratings in the last year.
The stock price for Pliant Therapeutics (NASDAQ: PLRX) is $16.83 last updated Today at September 29, 2023 at 3:30 PM UTC.
There is no dividend information for Pliant Therapeutics.
Pliant Therapeutics’s Q3 earnings are confirmed for Tuesday, November 7, 2023.
There is no upcoming split for Pliant Therapeutics.
Pliant Therapeutics is in the Health Care sector and Pharmaceuticals industry. They are listed on the NASDAQ.
Pliant Therapeutics Stock (NASDAQ: PLRX) stock price, news, charts, stock research, profile.
Open16.550 | Close- |
Vol / Avg.155.414K / 686.019K | Mkt Cap1.007B |
Day Range16.510 - 17.010 | 52 Wk Range14.470 - 36.640 |
Q3 2023 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | (EXPECTED) | ||||||
REV |
Q2 2023 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | -0.710 | -0.700 | 0.0100 | ||||
REV | 880.000K | 248.000K | -632.000K |
Date | Analyst Firm | Analyst Name | Action | Rating | Action Price | Prior Price | Target |
---|---|---|---|---|---|---|---|
2023-09-27 | HC Wainwright & Co. | Ed Arce | Maintains | BuyBuy | Raises | 50.00 | 52.00 |
2023-09-27 | Needham | Joseph Stringer | Reiterates | BuyBuy | Maintains | - | 45.00 |
2023-09-15 | Needham | Joseph Stringer | Reiterates | BuyBuy | Maintains | - | 45.00 |
2023-08-29 | HC Wainwright & Co. | Ed Arce | Reiterates | BuyBuy | Maintains | - | 50.00 |
Ticker | Company | Chg % | Mkt Cap |
---|---|---|---|
PLRX | Pliant Therapeutics | 2.62% | 1B |
GHRS | GH Research | -1.62% | 538.4M |
SUPN | Supernus Pharmaceuticals | -1.39% | 1.5B |
VRNA | Verona Pharma | -0.18% | 1.3B |
WVE | WAVE Life Sciences | -3.83% | 546.4M |
You can purchase shares of Pliant Therapeutics (NASDAQ: PLRX) through any online brokerage.
Other companies in Pliant Therapeutics’s space includes: GH Research (NASDAQ:GHRS), Supernus Pharmaceuticals (NASDAQ:SUPN), Verona Pharma (NASDAQ:VRNA), WAVE Life Sciences (NASDAQ:WVE) and CymaBay Therapeutics (NASDAQ:CBAY).
The latest price target for Pliant Therapeutics (NASDAQ: PLRX) was reported by HC Wainwright & Co. on Wednesday, September 27, 2023. The analyst firm set a price target for 52.00 expecting PLRX to rise to within 12 months (a possible 208.97% upside). 35 analyst firms have reported ratings in the last year.
The stock price for Pliant Therapeutics (NASDAQ: PLRX) is $16.83 last updated Today at September 29, 2023 at 3:30 PM UTC.
There is no dividend information for Pliant Therapeutics.
Pliant Therapeutics’s Q3 earnings are confirmed for Tuesday, November 7, 2023.
There is no upcoming split for Pliant Therapeutics.
Pliant Therapeutics is in the Health Care sector and Pharmaceuticals industry. They are listed on the NASDAQ.
Pliant Therapeutics Stock (NASDAQ: PLRX) stock price, news, charts, stock research, profile.
Open16.550 | Close- |
Vol / Avg.155.414K / 686.019K | Mkt Cap1.007B |
Day Range16.510 - 17.010 | 52 Wk Range14.470 - 36.640 |
Q3 2023 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | (EXPECTED) | ||||||
REV |
Q2 2023 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | -0.710 | -0.700 | 0.0100 | ||||
REV | 880.000K | 248.000K | -632.000K |
Date | Analyst Firm | Analyst Name | Action | Rating | Action Price | Prior Price | Target |
---|---|---|---|---|---|---|---|
2023-09-27 | HC Wainwright & Co. | Ed Arce | Maintains | BuyBuy | Raises | 50.00 | 52.00 |
2023-09-27 | Needham | Joseph Stringer | Reiterates | BuyBuy | Maintains | - | 45.00 |
2023-09-15 | Needham | Joseph Stringer | Reiterates | BuyBuy | Maintains | - | 45.00 |
2023-08-29 | HC Wainwright & Co. | Ed Arce | Reiterates | BuyBuy | Maintains | - | 50.00 |
Ticker | Company | Chg % | Mkt Cap |
---|---|---|---|
PLRX | Pliant Therapeutics | 2.62% | 1B |
GHRS | GH Research | -1.62% | 538.4M |
SUPN | Supernus Pharmaceuticals | -1.39% | 1.5B |
VRNA | Verona Pharma | -0.18% | 1.3B |
WVE | WAVE Life Sciences | -3.83% | 546.4M |
You can purchase shares of Pliant Therapeutics (NASDAQ: PLRX) through any online brokerage.
Other companies in Pliant Therapeutics’s space includes: GH Research (NASDAQ:GHRS), Supernus Pharmaceuticals (NASDAQ:SUPN), Verona Pharma (NASDAQ:VRNA), WAVE Life Sciences (NASDAQ:WVE) and CymaBay Therapeutics (NASDAQ:CBAY).
The latest price target for Pliant Therapeutics (NASDAQ: PLRX) was reported by HC Wainwright & Co. on Wednesday, September 27, 2023. The analyst firm set a price target for 52.00 expecting PLRX to rise to within 12 months (a possible 208.97% upside). 35 analyst firms have reported ratings in the last year.
The stock price for Pliant Therapeutics (NASDAQ: PLRX) is $16.83 last updated Today at September 29, 2023 at 3:30 PM UTC.
There is no dividend information for Pliant Therapeutics.
Pliant Therapeutics’s Q3 earnings are confirmed for Tuesday, November 7, 2023.
There is no upcoming split for Pliant Therapeutics.
Pliant Therapeutics is in the Health Care sector and Pharmaceuticals industry. They are listed on the NASDAQ.
Pliant Therapeutics Stock (NASDAQ: PLRX) stock price, news, charts, stock research, profile.
Open16.550 | Close- |
Vol / Avg.155.414K / 686.019K | Mkt Cap1.007B |
Day Range16.510 - 17.010 | 52 Wk Range14.470 - 36.640 |
Q3 2023 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | (EXPECTED) | ||||||
REV |
Q2 2023 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | -0.710 | -0.700 | 0.0100 | ||||
REV | 880.000K | 248.000K | -632.000K |
Date | Analyst Firm | Analyst Name | Action | Rating | Action Price | Prior Price | Target |
---|---|---|---|---|---|---|---|
2023-09-27 | HC Wainwright & Co. | Ed Arce | Maintains | BuyBuy | Raises | 50.00 | 52.00 |
2023-09-27 | Needham | Joseph Stringer | Reiterates | BuyBuy | Maintains | - | 45.00 |
2023-09-15 | Needham | Joseph Stringer | Reiterates | BuyBuy | Maintains | - | 45.00 |
2023-08-29 | HC Wainwright & Co. | Ed Arce | Reiterates | BuyBuy | Maintains | - | 50.00 |
Ticker | Company | Chg % | Mkt Cap |
---|---|---|---|
PLRX | Pliant Therapeutics | 2.62% | 1B |
GHRS | GH Research | -1.62% | 538.4M |
SUPN | Supernus Pharmaceuticals | -1.39% | 1.5B |
VRNA | Verona Pharma | -0.18% | 1.3B |
WVE | WAVE Life Sciences | -3.83% | 546.4M |
You can purchase shares of Pliant Therapeutics (NASDAQ: PLRX) through any online brokerage.
Other companies in Pliant Therapeutics’s space includes: GH Research (NASDAQ:GHRS), Supernus Pharmaceuticals (NASDAQ:SUPN), Verona Pharma (NASDAQ:VRNA), WAVE Life Sciences (NASDAQ:WVE) and CymaBay Therapeutics (NASDAQ:CBAY).
The latest price target for Pliant Therapeutics (NASDAQ: PLRX) was reported by HC Wainwright & Co. on Wednesday, September 27, 2023. The analyst firm set a price target for 52.00 expecting PLRX to rise to within 12 months (a possible 208.97% upside). 35 analyst firms have reported ratings in the last year.
The stock price for Pliant Therapeutics (NASDAQ: PLRX) is $16.83 last updated Today at September 29, 2023 at 3:30 PM UTC.
There is no dividend information for Pliant Therapeutics.
Pliant Therapeutics’s Q3 earnings are confirmed for Tuesday, November 7, 2023.
There is no upcoming split for Pliant Therapeutics.
Pliant Therapeutics is in the Health Care sector and Pharmaceuticals industry. They are listed on the NASDAQ.
Pliant Therapeutics Stock (NASDAQ: PLRX) stock price, news, charts, stock research, profile.
Open16.550 | Close- |
Vol / Avg.155.414K / 686.019K | Mkt Cap1.007B |
Day Range16.510 - 17.010 | 52 Wk Range14.470 - 36.640 |
Q3 2023 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | (EXPECTED) | ||||||
REV |
Q2 2023 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | -0.710 | -0.700 | 0.0100 | ||||
REV | 880.000K | 248.000K | -632.000K |
Date | Analyst Firm | Analyst Name | Action | Rating | Action Price | Prior Price | Target |
---|---|---|---|---|---|---|---|
2023-09-27 | HC Wainwright & Co. | Ed Arce | Maintains | BuyBuy | Raises | 50.00 | 52.00 |
2023-09-27 | Needham | Joseph Stringer | Reiterates | BuyBuy | Maintains | - | 45.00 |
2023-09-15 | Needham | Joseph Stringer | Reiterates | BuyBuy | Maintains | - | 45.00 |
2023-08-29 | HC Wainwright & Co. | Ed Arce | Reiterates | BuyBuy | Maintains | - | 50.00 |
Ticker | Company | Chg % | Mkt Cap |
---|---|---|---|
PLRX | Pliant Therapeutics | 2.62% | 1B |
GHRS | GH Research | -1.62% | 538.4M |
SUPN | Supernus Pharmaceuticals | -1.39% | 1.5B |
VRNA | Verona Pharma | -0.18% | 1.3B |
WVE | WAVE Life Sciences | -3.83% | 546.4M |
You can purchase shares of Pliant Therapeutics (NASDAQ: PLRX) through any online brokerage.
Other companies in Pliant Therapeutics’s space includes: GH Research (NASDAQ:GHRS), Supernus Pharmaceuticals (NASDAQ:SUPN), Verona Pharma (NASDAQ:VRNA), WAVE Life Sciences (NASDAQ:WVE) and CymaBay Therapeutics (NASDAQ:CBAY).
The latest price target for Pliant Therapeutics (NASDAQ: PLRX) was reported by HC Wainwright & Co. on Wednesday, September 27, 2023. The analyst firm set a price target for 52.00 expecting PLRX to rise to within 12 months (a possible 208.97% upside). 35 analyst firms have reported ratings in the last year.
The stock price for Pliant Therapeutics (NASDAQ: PLRX) is $16.83 last updated Today at September 29, 2023 at 3:30 PM UTC.
There is no dividend information for Pliant Therapeutics.
Pliant Therapeutics’s Q3 earnings are confirmed for Tuesday, November 7, 2023.
There is no upcoming split for Pliant Therapeutics.
Pliant Therapeutics is in the Health Care sector and Pharmaceuticals industry. They are listed on the NASDAQ.
Pliant Therapeutics Stock (NASDAQ: PLRX) stock price, news, charts, stock research, profile.
Open16.550 | Close- |
Vol / Avg.155.414K / 686.019K | Mkt Cap1.007B |
Day Range16.510 - 17.010 | 52 Wk Range14.470 - 36.640 |
Q3 2023 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | (EXPECTED) | ||||||
REV |
Q2 2023 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | -0.710 | -0.700 | 0.0100 | ||||
REV | 880.000K | 248.000K | -632.000K |
Date | Analyst Firm | Analyst Name | Action | Rating | Action Price | Prior Price | Target |
---|---|---|---|---|---|---|---|
2023-09-27 | HC Wainwright & Co. | Ed Arce | Maintains | BuyBuy | Raises | 50.00 | 52.00 |
2023-09-27 | Needham | Joseph Stringer | Reiterates | BuyBuy | Maintains | - | 45.00 |
2023-09-15 | Needham | Joseph Stringer | Reiterates | BuyBuy | Maintains | - | 45.00 |
2023-08-29 | HC Wainwright & Co. | Ed Arce | Reiterates | BuyBuy | Maintains | - | 50.00 |
Ticker | Company | Chg % | Mkt Cap |
---|---|---|---|
PLRX | Pliant Therapeutics | 2.62% | 1B |
GHRS | GH Research | -1.62% | 538.4M |
SUPN | Supernus Pharmaceuticals | -1.39% | 1.5B |
VRNA | Verona Pharma | -0.18% | 1.3B |
WVE | WAVE Life Sciences | -3.83% | 546.4M |
You can purchase shares of Pliant Therapeutics (NASDAQ: PLRX) through any online brokerage.
Other companies in Pliant Therapeutics’s space includes: GH Research (NASDAQ:GHRS), Supernus Pharmaceuticals (NASDAQ:SUPN), Verona Pharma (NASDAQ:VRNA), WAVE Life Sciences (NASDAQ:WVE) and CymaBay Therapeutics (NASDAQ:CBAY).
The latest price target for Pliant Therapeutics (NASDAQ: PLRX) was reported by HC Wainwright & Co. on Wednesday, September 27, 2023. The analyst firm set a price target for 52.00 expecting PLRX to rise to within 12 months (a possible 208.97% upside). 35 analyst firms have reported ratings in the last year.
The stock price for Pliant Therapeutics (NASDAQ: PLRX) is $16.83 last updated Today at September 29, 2023 at 3:30 PM UTC.
There is no dividend information for Pliant Therapeutics.
Pliant Therapeutics’s Q3 earnings are confirmed for Tuesday, November 7, 2023.
There is no upcoming split for Pliant Therapeutics.
Pliant Therapeutics is in the Health Care sector and Pharmaceuticals industry. They are listed on the NASDAQ.